Oslo-based Tribune Therapeutics has raised $40 million to advance its way of inhibiting the formation of scar tissue in disease. The cash from investors including LifeArc Ventures, Novo Holdings, and ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

From today, the updated indication for TRIKAFTA is as follows: TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

Cystic fibrosis (CF) patients could be given access to a new drug on the NHS by the end of the year if it is given the green ...

The genetic condition cystic fibrosis had no treatments on the NHS before 2019 and a Daily Express campaign - now a miracle ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) ...

Shares of Vertex Pharmaceuticals Incorporated VRTX rose 2.4% on its cystic fibrosis drug Alyftrek getting approval in the United Kingdom. Shares of Tesla, Inc. TSLA plummeted 15.4% on the broad ...